Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
Cortical Lesions in Primary Progressive Multiple Sclerosis: A 2-Year Longitudinal MR Study
Neurol 72:1330-1336, Calabrese,M.,et al, 2009
Assessment of Normal-Appearing White and Gray Matter in Patients with Primary Progressive Multiple Sclerosis
Arch Neurol 59:1406-1412, Rovaris,M.,et al, 2002
The Prevalence of Sjogren Syndrome in Patients with Primary Progressive Multiple Sclerosis
Neurol 57:1359-1363,1357, de Seze,J.,et al, 2001
Primary and Transitional Progressive MS,A Clinical and MRI Cross-Sectional Study
Neurol 52:839-845, Stevenson,V.L.,et al, 1999
Comparison of Triple Dose vs Std Dose Gadolinium-DTPA for Detect of MRI Enhanc Lesions in Pts with Primary Progr MS
JNNP 59:540-544, Filippi,M.,et al, 1995